Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Sam Schulman(Thrombosis and Atherosclerosis Research Institute), Samuel Z. Goldhaber(Brigham and Women's Hospital), Janet Schnee(Boehringer Ingelheim (United States)), David Baanstra(Boehringer Ingelheim (Netherlands)), Ajay K. Kakkar(Thrombosis Research Institute), Patrick Mismetti, Clive Kearon(McMaster University), Henry Eriksson(Sahlgrenska University Hospital), Sebastian Schellong(Städtisches Klinikum Dresden)
Cited by 2,565
Related Papers
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
|Journal of Thrombosis and Haemostasis|2005|4.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
|Journal of Thrombosis and Haemostasis|2009|3.8k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Prevention of VTE in Nonsurgical Patients
|CHEST Journal|2012|2.7k